{"id":"9a70989a-04c6-5f0a-ba7d-4e4c93dfff7c","stable_key":"31b1baa4-4113-5541-b9e7-fe44a5253a07:mouse-bv2-nrf2-nuclear","predicate":"increases_in_recorded_experiment","statement":"Shikimic acid increased nuclear Nrf2 accumulation in BV2 cells.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"9bdcb1e3-c2d7-5404-a8ab-bbeabfdeb0b4","mechanism_event_label":"Shikimic acid increased nuclear Nrf2 accumulation in BV2 cells.","subject":{"id":"67ad4a8f-1bf6-59e5-90a6-97b7709024d3","slug":"shikimic-acid","display_name":"Shikimic acid","entity_type_key":"small_molecule"},"object":{"id":"83e40444-8c9b-59bf-a54f-0ed04f43bfb0","slug":"mouse-bv2-nrf2-nuclear","display_name":"Mouse BV2 nuclear Nrf2 accumulation","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"9bdcb1e3-c2d7-5404-a8ab-bbeabfdeb0b4","stable_key":"31b1baa4-4113-5541-b9e7-fe44a5253a07:mouse-bv2-nrf2-nuclear-event","event_type":"experimental_observation","label":"Shikimic acid increased nuclear Nrf2 accumulation in BV2 cells.","description":"**AKT and Nrf2 involvement does not identify the binding target.** BV2 experiments recorded increased AKT phosphorylation and nuclear Nrf2. MK2206 pretreatment attenuated Nrf2 activation and partially reversed redox/nitrite responses. A reagent labeled RA also attenuated the Nrf2 response; its identity and selectivity are not independently resolved here, so no vitamin-A or retinoic-acid interaction is created from that abbreviation. Pharmacological perturbation supports pathway involvement while leaving the initiating target and off-target alternatives open. [Shikimic acid (SA) inhibits neuro-inflammation and exerts neuroprotective effects in an LPS-induced <i>in vitro</i> and <i>in vivo</i> model.](https://pubmed.ncbi.nlm.nih.gov/38026972/)","status":"provisional","compartment":null,"participants":[{"entity":{"id":"67ad4a8f-1bf6-59e5-90a6-97b7709024d3","slug":"shikimic-acid","display_name":"Shikimic acid","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"Shikimic acid","sequence_order":0,"notes":""},{"entity":{"id":"83e40444-8c9b-59bf-a54f-0ed04f43bfb0","slug":"mouse-bv2-nrf2-nuclear","display_name":"Mouse BV2 nuclear Nrf2 accumulation","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"increase","sequence_order":1,"notes":""},{"entity":{"id":"95319607-3946-51b3-8235-400ec3223692","slug":"mouse-nfe2l2","display_name":"Mouse Nrf2 / Nfe2l2","entity_type_key":"protein"},"role":"measured pathway component","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text retrieved; relevant methods/results/figures reviewed. Selective extraction, not raw-data reanalysis or exhaustive supplemental extraction.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Shikimic acid\", \"comparator\": \"Matched cells without SA\", \"endpoint\": \"Shikimic acid increased nuclear Nrf2 accumulation in BV2 cells.\", \"effect_direction\": \"increase\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; source-derived draft.","entity":null},{"dimension":"experimental_model","value_text":"Mouse BV2 signaling time-course.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Pathway response is not direct ligand binding or clinical efficacy.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Shikimic acid increased nuclear Nrf2 accumulation in BV2 cells.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Shikimic acid (SA) inhibits neuro-inflammation and exerts neuroprotective effects in an LPS-induced <i>in vitro</i> and <i>in vivo</i> model. | 2023 | DOI 10.3389/fphar.2023.1265571 | PMID 38026972 | https://pubmed.ncbi.nlm.nih.gov/38026972/ | https://doi.org/10.3389/fphar.2023.1265571 | https://pmc.ncbi.nlm.nih.gov/articles/PMC10652795/","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference lines 61-61; exact primary location described in quoted passage where extracted.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"abae640f-06ab-53c4-b7b2-ff008a4c520a","evidence_kind":"source_excerpt","locator":"Lines 61-61","start_line":61,"end_line":61,"excerpt":"**AKT and Nrf2 involvement does not identify the binding target.** BV2 experiments recorded increased AKT phosphorylation and nuclear Nrf2. MK2206 pretreatment attenuated Nrf2 activation and partially reversed redox/nitrite responses. A reagent labeled RA also attenuated the Nrf2 response; its identity and selectivity are not independently resolved here, so no vitamin-A or retinoic-acid interaction is created from that abbreviation. Pharmacological perturbation supports pathway involvement while leaving the initiating target and off-target alternatives open. [Shikimic acid (SA) inhibits neuro-inflammation and exerts neuroprotective effects in an LPS-induced <i>in vitro</i> and <i>in vivo</i> model.](https://pubmed.ncbi.nlm.nih.gov/38026972/)","model_system":"Mouse BV2 signaling time-course.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact excerpt of the retained AI-assisted reviewed reference; primary sources are cited in primary_references and access scope is retained. Not a verbatim quotation from a primary paper.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"e6ae59de-0369-5c2f-8262-57d91302671c","stable_key":"import-31b1baa4-4113-5541-b9e7-fe44a5253a07","title":"Shikimic acid: detailed mechanisms of action (reviewed 5 October 2026)","document_type":"imported_text","citation_label":"Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication.","file_path":"","sha256":"95b1f9e9577661312d67f36e156d2e49326b207f296c1c0e801a5b007fd8e283","revision_id":"cd3237f1-131a-557d-84b5-7543259807b0","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}